RESUMEN
Bone turnover markers (BTM) are highly responsive to initiation and changes in anti-osteoporotic therapy. In contrast to the slow treatment-induced changes in bone mineral density, the fast changes in BTM enable the clinician to adjust treatment management within a short timeframe. This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described.
Asunto(s)
Conservadores de la Densidad Ósea , Osteoporosis , Humanos , Biomarcadores , Osteoporosis/tratamiento farmacológico , Densidad Ósea , Remodelación Ósea , Denosumab/uso terapéuticoAsunto(s)
Densidad Ósea , Remodelación Ósea , Humanos , Niño , Adolescente , Absorciometría de Fotón , Factores de EdadRESUMEN
This review discusses two methods of monitoring the effect of anti-osteoporotic treatment: bone mineral density (BMD) and bone turnover markers (BTMs). Both monitoring strategies are to some extent able to predict the treatment-induced change in risk of fracture. The use of BMD is commonplace, and clinicians are experienced in the interpretation of data. The use and knowledge of BTMs among clinicians is limited, but it allows for early testing while being practical and cheap. Further knowledge and implementation of BTMs in the clinical practice may improve the monitoring capabilities.